PENTOSTATIN

SynDRA canonical compound SYN0011750 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	ADA
Mechanism of action	adenosine deaminase inhibitor \| adenosine deaminase inhibitor, ribonucleotide reductase inhibitor \| ribonucleotide reductase inhibitor
Indication	hairy cell leukemia
Disease area	hematologic malignancy

All known targets

deoxycoformycin
NSC218321
Pentostatine
Pentostatina
Deoxycoformycin
CI-825
NSC-218321
PD-81565
YK-176
Nipent
Coforin
Covidarabine
Oncopent
Vidarbine
Vira A deaminase inhibitor
CL-67310465
CO-Vidarabine
Co-V
Nipent (TN)
PD-ADI
Pentostatin (JAN/USAN/INN)
(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
2'-DCF
2'-Deoxycoformycin
2'-Dexoycoformycin
NSC 218321
395575MZO7
(8R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol
NCGC00182045-01
Deaminase inhibitor (PD)
(R)-3-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
Pentostatinum
(R)-2'-Deoxycoformycin
(R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
(R)-Deoxycoformycin